Cargando…
Modulation of Reoviral Cytolysis (I): Combination Therapeutics
Patients with stage IV gastric cancer suffer from dismal outcomes, a challenge especially in many Asian populations and for which new therapeutic options are needed. To explore this issue, we used oncolytic reovirus in combination with currently used chemotherapeutic drugs (irinotecan, paclitaxel, a...
Autores principales: | Mori, Yoshinori, Nishikawa, Sandra G., Fratiloiu, Andreea R., Tsutsui, Mio, Kataoka, Hiromi, Joh, Takashi, Johnston, Randal N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385176/ https://www.ncbi.nlm.nih.gov/pubmed/37515160 http://dx.doi.org/10.3390/v15071472 |
Ejemplares similares
-
Modulation of Reoviral Cytolysis (II): Cellular Stemness
por: Bourhill, Tarryn, et al.
Publicado: (2023) -
Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection
por: Bourhill, Tarryn, et al.
Publicado: (2018) -
Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells
por: Inagaki, Yusuke, et al.
Publicado: (2017) -
Type I interferon signaling limits reoviral tropism within the brain and prevents lethal systemic infection
por: Dionne, Kalen R., et al.
Publicado: (2011) -
Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease
por: Ozeki, Keiji, et al.
Publicado: (2012)